Haemonetics Co. (NYSE:HAE) Position Lifted by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC raised its stake in shares of Haemonetics Co. (NYSE:HAE) by 31.0% during the fourth quarter, HoldingsChannel reports. The fund owned 643,227 shares of the medical instruments supplier’s stock after acquiring an additional 152,042 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Haemonetics were worth $50,223,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its stake in Haemonetics by 40.7% during the 4th quarter. ProShare Advisors LLC now owns 16,486 shares of the medical instruments supplier’s stock valued at $1,287,000 after acquiring an additional 4,771 shares during the last quarter. Nomura Holdings Inc. bought a new position in Haemonetics during the 4th quarter valued at $519,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Haemonetics by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,570 shares of the medical instruments supplier’s stock worth $2,231,000 after buying an additional 1,084 shares during the last quarter. LMR Partners LLP bought a new position in shares of Haemonetics in the 4th quarter worth about $2,059,000. Finally, London Co. of Virginia lifted its position in shares of Haemonetics by 2.2% in the 4th quarter. London Co. of Virginia now owns 281,738 shares of the medical instruments supplier’s stock worth $21,998,000 after buying an additional 6,111 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Raymond James restated a “strong-buy” rating and issued a $105.00 price target (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday. JMP Securities dropped their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC dropped their price objective on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.89.

Haemonetics Stock Up 1.0%

Haemonetics stock opened at $69.36 on Friday. The stock has a market cap of $3.48 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 1.11 and a beta of 0.32. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company’s 50-day moving average price is $62.88 and its two-hundred day moving average price is $71.24. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $96.14.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analysts’ expectations of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS. On average, analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.